Quarterly ResultJul 30, 2026, 04:09 PM
PTC Therapeutics Q2 Revenue $361M; Raises Full-Year Guidance
AI Summary
PTC Therapeutics announced strong second quarter 2026 financial results, with total revenue reaching $361 million and product revenue at $239 million. The company raised its full-year 2026 total revenue guidance to $1.18 billion to $1.28 billion and product revenue guidance to $850 million to $950 million. Additionally, Hege Sollie-Zetlmayer, former Chief Human Resources Officer, was appointed to the Board of Directors, effective immediately.
Key Highlights
- Q2 2026 total revenue was $361 million, including $239 million of product revenue.
- Sephience Q2 2026 revenue reached $151 million, with 1,647 patients on commercial therapy worldwide.
- Received a $50 million development milestone payment from Novartis for INVEST-HD Phase 3 study initiation.
- Full-year 2026 total revenue guidance increased to $1.18 billion to $1.28 billion.
- Full-year 2026 product revenue guidance raised to $850 million to $950 million.
- Cash, cash equivalents, and marketable securities stood at $2.23 billion as of June 30, 2026.
- Hege Sollie-Zetlmayer, former CHRO, appointed to the Board of Directors as a Class III director.
Price Impact
More from PTCT